The Goal of the study is to evaluate the rate of myopia progression with open ring myopia control spectacle lens designs compared to a commercial peripheral plus myopia control spectacle lens (CML) in European children with myopia. This is a prospective, randomized, bilateral wear, double masked, cross-over clinical trial. There will be a total of 180 participants randomized into three groups, Group 1 - 60 participants will wear the commercial peripheral plus myopia control lens (CML).
Group 2 - 60 participants will wear the Open Ring 1 (OR1) lens design. Group 3 - 60 participants will wear the Open Ring 2 (OR2) lens design. For each group, an equal balance of gender will be recruited and 50% of children will be aged between 6- 9 years old and 50% aged 10-12 years old. All groups will be required to wear spectacles for all waking hours for 12 months. After 12 months, the control group will continue wearing CML for a further 12 months; the Group 2 participants will continue wearing the OR1 lens for a further 12 months. The Group 3 participants will wear OR2 or OR3 (a modified design of OR2) based on their risk of myopia progression for a further 12 months

Start Date01 Apr 2026

Sponsor / Collaborator

University of Ulster

[+2]

ISRCTN16260195

/ Not yet recruitingNot ApplicableIIT

The effects of fish consumption and omega 3 supplementation in reducing risk of cardiovascular disease in young adults (CardioFish)

Start Date02 Feb 2026

Sponsor / Collaborator

University of Ulster

NCT07349290

/ Enrolling by invitationNot ApplicableIIT

Vitamin D (Bio)Fortified Shopping Baskets to Improve Vitamin D Status: a Household-level RCT

Vitamin D is essential for healthy bones, muscles, and immune function. It comes from food, supplements, and sunlight. There are two main forms; vitamin D2, found mainly in plant foods, and vitamin D3, which comes from animal foods and is more effective at increasing vitamin D levels in the body. In the UK, sunlight is often too weak especially in winter for the body to make enough vitamin D, so people rely mainly on dietary sources and supplements. Despite this, many people in the UK have low vitamin D levels, and teenagers are particularly at risk due to increased needs during growth, with around one in five adolescents having low vitamin D levels. Poor intake of vitamin D-rich foods, low supplement use, and inconsistent food fortification contribute to this problem. This study aims to assess whether a family-based household diet using natural and fortified vitamin D foods during winter can improve vitamin D levels in adolescents.

Start Date01 Jan 2026

Sponsor / Collaborator

University of Ulster

[+2]

100 Clinical Results associated with University of Ulster

0 Patents (Medical) associated with University of Ulster

7,398

Literatures (Medical) associated with University of Ulster

01 May 2026·JOURNAL OF AFFECTIVE DISORDERS

Longitudinal trajectories of depression across adolescence, emerging adulthood and adulthood: Findings from the national longitudinal study of adolescent to adult health (add health) (1994–2008)

Article

Author: McBride, Orla ; Ross, Catriona ; Adamson, Gary ; Henderson, Ellen

BACKGROUND:

The heterogeneity of depression is well documented. Consistent with the Life Course Theory, longitudinal analysis establishing trajectories may demonstrate the stability and variation of depression.

METHODS:

Data from four waves of the US National Longitudinal Study of Adolescent to Adult Health (Add Health) were used to investigate depression trajectories. Nine items from the Center for Epidemiological Studies (CESD) measured depression of 9421 participants. Trajectories were established using growth mixture modelling (GMM) and multinomial regression was employed to explore the influence of gender and ethnicity.

RESULTS:

Five distinct and unique trajectories were established as minimal (66.8%), moderate (19.1%), Emerging Adulthood (EA) trough (7.6%), persistently high (3.3%) and EA peak (3.1%). Being female and non-white increased the probability of being in the elevated trajectories during adolescence.

CONCLUSION:

Three stable and two fluctuating trajectories demonstrate both the predictability and heterogeneity of depression across three distinct developmental stages.

02 Feb 2026·ACS Applied Bio Materials

A Low-Cost Paper-Based Electrochemical Aptasensor for HER-2 Detection Using Ti ₃ C ₂ T _x MXene

Article

Author: Singh, Sonam ; Goswami, Tapas ; Mathur, Ashish ; Singh, Garima ; McLaughlin, James ; Rawat, Reema

Breast cancer remains a leading cause of mortality among women worldwide, emphasizing the need for early, rapid, and cost-effective diagnostic tools. In this study, we report a low-cost, paper-based electrochemical aptasensor for the specific detection of human epidermal growth factor receptor 2 (HER-2), a critical biomarker associated with breast cancer progression. The sensor was fabricated on a carbon screen-printed paper electrode (CSPPE) modified with Ti₃C₂T_x MXene, a two-dimensional transition metal carbide providing excellent conductivity and abundant surface sites for aptamer immobilization. The HER-2-specific aptamer was covalently attached onto the MXene surface via EDC-NHS coupling, and methylene blue (MB) served as a redox mediator to monitor binding events. The developed biosensor exhibited excellent analytical performance, achieving a wide linear detection range from 10 fg/mL to 100 μg/mL, a limit of detection (LOD) of 9.3 fg/mL, a limit of quantification (LOQ) of 28.4 fg/mL and a sensitivity of 10.05 μA/fg/mL/mm². Furthermore, the aptasensor demonstrated high selectivity, reproducibility, and operational stability, maintaining its sensing performance for up to one month under ambient storage conditions. The integration of MXene's superior electrical conductivity with a disposable paper-based platform presents a highly promising approach for point-of-care HER-2 detection, contributing toward accessible, rapid, and cost-effective breast cancer diagnostics.

01 Feb 2026·JOURNAL OF STRENGTH AND CONDITIONING RESEARCH

Effects of Three Different Volumes of In-Water Warm-Up Protocols in Acute Physiologic Responses and 100 m Swimming Performance Across All Strokes

Article

Author: Saini, Ankur S. ; McCabe, Carla ; Phukan, Max I. ; Thapa, Rohit K. ; Kushwah, Gaurav S. ; Sharma, Sudhir K.

Abstract:

Saini, AS, Sharma, SK, Kushwah, GS, Phukan, MI, McCabe, C, and Thapa, RK. Effects of three different volumes of in-water warm-up protocols in acute physiologic responses and 100 m swimming performance across all strokes. J Strength Cond Res 40(2): 191–197, 2026—This study examined the effects of 3 in-water warm-up (WU) protocols of varying volumes (600, 1,200, and 1,800 m) on acute physiologic responses and 100-m swimming performance across all strokes. Forty male national-level swimmers (21.0 ± 2.0 years) participated in a randomized crossover study, performing each WU protocol followed by a 100-m time trial in their respective strokes. Physiologic metrics, including blood lactate, temperature, heart rate, and rating of perceived exertion (RPE), were recorded. A repeated measures ANOVA was used to investigate the effects of the 3 protocols on physiologic and swimming performance across all the strokes. Results showed that the regular WU (1,200 m) led to significantly faster times in backstroke (65.56 ± 1.14 seconds vs 67.02 ± 1.20 seconds), breaststroke (70.73 ± 0.94 seconds vs 72.73 ± 0.94 seconds), and butterfly (58.64 ± 0.77 seconds vs 60.53 ± 0.86 seconds) than the long WU (1,800 m) ( p < 0.05). For the butterfly, the short WU (600 m) also resulted in significantly better swimming performance than the long WU. No significant differences were observed in freestyle performance among the 3 WU protocols, nor were there differences in heart rate across all strokes ( p > 0.05). Higher blood lactate and tympanic temperatures were observed after regular WU, while RPE was lowest after the short WU. This study emphasizes the importance of optimizing WU volumes based on stroke-specific demands in swimming. In addition, it also suggests practitioners to be cautious about using heart rate as a sole marker of WU effectiveness in swimming.

News (Medical) associated with University of Ulster

12 Jan 2026

·www.prnewswire.com

PulseAI Secures Seed Funding to Advance AI-Driven ECG Diagnostics

BELFAST, Northern Ireland , Jan. 12, 2026 /PRNewswire/ -- PulseAI, a rapidly emerging leader in AI-enabled cardiac diagnostics, today announced the closing of its seed funding round, led by Innovation Ulster Limited, with participation from The Mortara Group and The Francis Crick Institute. The investment will enable PulseAI to scale deployment of its AI-ECG technology and advance its pathway through US FDA 510(k) clearance. Over 300 million electrocardiograms (ECGs) are performed annually worldwide. However, despite the critical importance of the ECG as a frontline diagnostic tool, its interpretation remains highly dependent on specialist training and manual analysis. This often leads to delays, diagnostic variability, and missed opportunities for early intervention. PulseAI's AI-ECG platform is designed to address this challenge directly by delivering high-performance clinical decision support in both primary and acute care settings. As part of the round, Dr. Justin Mortara, an experienced innovator in ECG technologies and former CEO of Mortara Instruments, will join PulseAI as Chair of the Board, strengthening the company's strategic alignment with global leaders in cardiac monitoring, diagnostics, and hospital systems. PulseAI's technology, trained on large-scale ECG datasets and validated in partnership with some of the world's leading institutions across Europe and the United States, promises to bring the power of AI to one of the most widely used diagnostic tests. The new investment will accelerate: Regulatory advancement, including FDA 510(k), further clinical validation across diverse populations and care settings Productisation for enterprise and OEM integration Expansion of partnerships with device manufacturers and hospital networks "This investment marks a pivotal moment for PulseAI as we move into full clinical and regulatory execution," said Dr Alan Kennedy, Founder and CEO of PulseAI. "Our goal is to deliver advanced ECG technology that can expedite and improve the accuracy of cardiac diagnostics, reducing variability and expanding access to high-quality diagnostics in all areas of healthcare." "PulseAI sits at the intersection of clinical rigour, scalable technology, and real market need," said Justin Mortara, incoming Chair of the Board. "The company is building a platform with the potential to elevate ECG interpretation across the entire care continuum, pairing its AI with traditional medical devices as well as a growing array of consumer wearables. I'm excited to support the team as they move through regulatory milestones to broader industry adoption" SOURCE PulseAI 21% more press release views with Request a Demo

Diagnostic Reagents

08 Jan 2026

·www.prnewswire.com

NIH Awards Major Grant to The University of California LA to Advance Groundbreaking Research in Cognitive Health

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Juice Plus+ is proud to announce a research collaboration with the University of California LA, University College Cork (Ireland) and Ulster University (Northern Ireland). For this randomized clinical trial the University of California LA received a major research grant from the National Institutes of Health (NIH), a globally recognized institution of scientific excellence. The NIH, renowned for supporting only the highest caliber of medical research, has chosen to fund an innovative project aimed at better understanding critical cognitive functional parameters in the brain and related biomarkers. With the long term goal of identifying factors influencing cognitive performance and overall well-being. NIH grants are awarded following a rigorous review process by world-leading experts and scientists, ensuring only the most promising and evidence-based proposals receive support. As part of the US - Ireland R&D Partnership Programme the University College Cork has also received a grant from Research Ireland, and Ulster University received a grant from the Health & Social Care R&D Division Northern Ireland. These fundings reflect peer recognition of the scientific approach being taken by the university researchers. Research Focus and Endpoints* This 5-year project is designed to evaluate the effects Juice Plus+® Berry Blend may have on brain and cognitive parameters and related biomarkers, in a cohort of male and female participants, aged 50+ years, with a family history of age related cognitive decline. This randomized, double-blinded, placebo-controlled study is being performed at the University of California LA and Ulster University in Northern Ireland. Commitment to Scientific Excellence We are honored to collaborate with our esteemed academic partners in this important research initiative. We look forward to contributing to the scientific understanding of cognitive health through rigorous, independent research conducted by leading academic institutions. *This information does not constitute endorsement by any funding agency or university. Juice Plus+ is providing the investigational product but is not involved in study design, conduct, or data analysis. Media contact: [email protected] SOURCE Juice Plus 21% more press release views with Request a Demo

21 Jul 2025

·www.prnewswire.com

Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer

PHILADELPHIA, July 21, 2025 /PRNewswire/ -- Minaris Advanced Therapies is pleased to announce the appointment of Dr. Orla Cloak as Chief Executive Officer. Continue Reading Dr. Orla Cloak, Recently Appointed Chief Executive Officer, Minaris Advanced Therapies Dr. Cloak is a seasoned executive with over 20 years of commercial leadership experience in the Pharma and Life Science industries. She brings with her a proven track record of driving innovation, operational excellence, sustainable business growth and strategic leadership. Prior to joining Minaris Advanced Therapies, Orla held several leadership positions at Lonza over a 17-year period, most recently serving as Senior Vice President and Head of the Lonza Bioscience business. She holds a Bachelor of Science Degree from University College Dublin and a Doctorate in Microbiology from the University of Ulster. Iain Baird, Chairman of the Board, Minaris Advanced Therapies commented : "On behalf of the board, I am delighted to welcome Orla to Minaris Advanced Therapies. Her leadership will be instrumental to achieving our mission of supporting customers to successfully commercialize their innovative therapies." Orla Cloak, Chief Executive Officer, Minaris Advanced Therapies commented: "I am honored to join Minaris Advanced Therapies at such a pivotal time. I look forward to working with the talented team here to build on the company's strong foundations and drive its next phase of growth." About Minaris Advanced Therapies: Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on Cell and Gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 650,000 square feet of infrastructure across the United States, Europe and Asia. The organization has manufactured and released over 7,500 GMP batches and has a global network that supports therapy developers through early-stage development, clinical trials and commercial manufacturing. Minaris Advanced Therapies is a portfolio company of Altaris. About Altaris: Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare sub-sectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit Media Contact: Tihesha Aaron [email protected] SOURCE Minaris Advanced Therapies, LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive ChangeGene Therapy

100 Deals associated with University of Ulster

100 Translational Medicine associated with University of Ulster

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 17 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Ac3IV ( AVPR1A x AVPR1B )	Obesity More	Preclinical
InflaMab ( NLRP3 )	Glaucoma More	Preclinical
L132P KRT12 siRNA-sshLNPs(University of Ulster)	Corneal Dystrophy, Juvenile Epithelial of Meesmann More	Preclinical
(Val8)GLP-1(Ulster University) ( GLP-1R )	Alzheimer Disease More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis